ValiRx

www.valirx.com TICKER: VAL     EXCHANGE: AIM

Valirx is a semi-virtual, emerging biopharmaceutical company based in London and listed on the Alternative Investment Market. It is focused on the development and commercialisation of ground breaking and disruptive gene silencing technologies for the development of a novel class of oncology therapeutics and diagnostics. The Company operates through two subsidiaries: ValiPharma and ValiMedix. ValiPharma is developing GeneICE (Gene Inactivation by Chromatin Engineering), a novel DNA silencing technology platform able to silence cancer causing genes. GeneICE consists of two synthetic molecule constructs, an oligonucleotide and a gene repression peptide. GeneICE construct is an epigenetic alternative to antisense and RNAi technologies. GeneICE drug candidates and control molecules are currently undergoing efficacy and safety studies. The R&D pipeline includes 2 pre-clinical compounds Val101 and Val201. Vali101 development is being financed through the awarding of 1.2m by the EUREKA EuroStars programme, a Pan-European collaborative initiative. The consortium consists of PentaBase (Denmark) and GenoSyst (Finland) with ValiRx being the leader. ValiMedix is an e-commerce distribution platform selling Over-the-Counter SELF-test diagnostic screening kits.

LATEST REPORTS

 
Seasonal tidings
Published: Dec 15 2009

This biopharmaceutical company has announced a £3m equity line of credit over a two year period

Further R& D development links are also being made in Finland

 
Update
Published: Sep 29 2009

Recent financing from equity, and grants to come

Operational progress in all R&D projects

Dilution does not erode potential for returns

 
Global Distribution Agreement
Published: Dec 16 2008

ValiRx is ending the financial year on a positive note by signing an exclusive global distribution agreement for ValiBio's entire diagnostic product portfolio (ex-Belgium for 2 diagnostics). Furthermore, it is securing a cash inflow of 600k (c.£537k) through the  sale of a 10% stake of its wholly-owned Belgium-based diagnostic subsidiary to Biofield Corporation.
 
Full year results in line with prior expectations
Published: Aug 05 2008

Successful equity placings

Expanded patent estate

Progression of the cancer therapeutic pipeline

Optional in-licensing deal

Fair value / share seen at 21.9p, still materially above current level (6p)
 
GeneICE in vitro studies successfully completed
Published: Jan 25 2008

Collaboration agreement in place with Physiomics

Morphogenesis developing cell separation device

New Chairman appointed

Fair value (unchanged) seen at 33p / share versus current 10p

 
Pursuit of Cancer diagnosis and treatment
Published: Oct 01 2007

Two compounds in advanced pre-clinical trials

A number of research collaboration agreements

Profitability seen in 2009, discounted PER valuation seen well above current price

ARCHIVE